Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDDate | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
---|---|---|---|---|---|---|
10/31/2024 | Q3 2024 | $0.62 | $244.00 M | |||
08/12/2024 | Q2 2024 | -$0.07 | $604.34 M | |||
05/02/2024 | Q1 2024 | -$0.05 | $535.68 M | |||
12/30/2023 | Q4 2023 | $0.02 | $0 | |||
09/29/2023 | Q3 2023 | $0.03 | $0 | |||
06/29/2023 | Q2 2023 | -$0.40 | $0 | |||
03/30/2023 | Q1 2023 | -$0.59 | $0 | |||
12/30/2022 | Q4 2022 | -$0.18 | $0 | |||
09/29/2022 | Q3 2022 | -$0.01 | $0 | |||
06/28/2022 | Q2 2022 | -$0.01 | $0 | |||
03/30/2022 | Q1 2022 | -$0.00 | $0 | |||
12/29/2021 | Q4 2021 | -$0.00 | $0 |
Conduit Pharmaceuticals Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, November 18th, 2024 based off last year's report dates.
The conference call for Conduit Pharmaceuticals Inc.'s latest earnings report can be listened to online.
The conference call transcript for Conduit Pharmaceuticals Inc.'s latest earnings report can be read online.
Conduit Pharmaceuticals Inc. (:CDT) has a recorded net income of $0. Conduit Pharmaceuticals Inc. has generated $-0.0904 earnings per share over the last four quarters.
Conduit Pharmaceuticals Inc. (:CDT) has a price-to-earnings ratio of -0.48 and price/earnings-to-growth ratio is -0.
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTED